Mankind Pharma Limited (MANKIND)
Press Release
Press Release - Q1FY27
- Revenue 4031 Cr +12.9% y-y; EBITDA 1060 Cr +24.7% y-y (margin 26.3%, +250 bps y-y); PAT 574 Cr +29.1% y-y
- Domestic revenue grew 10.5% with strong double-digit growth in chronic therapies and BSV specialty
- Exports surged 29% with 1 new product launch in the US, total 49 products launched
- Consumer Healthcare grew 4%, gaining market share in key brands
- EBITDA margin expansion driven by disciplined execution and business fundamentals strengthening
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 MANKIND — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add MANKIND to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Mankind Pharma Limited
Important.
The summary above is generated automatically from Mankind Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.